全文获取类型
收费全文 | 83425篇 |
免费 | 7642篇 |
国内免费 | 3233篇 |
专业分类
耳鼻咽喉 | 160篇 |
儿科学 | 4410篇 |
妇产科学 | 659篇 |
基础医学 | 6266篇 |
口腔科学 | 576篇 |
临床医学 | 8466篇 |
内科学 | 13404篇 |
皮肤病学 | 594篇 |
神经病学 | 1664篇 |
特种医学 | 2278篇 |
外国民族医学 | 14篇 |
外科学 | 29846篇 |
综合类 | 11419篇 |
一般理论 | 2篇 |
预防医学 | 2199篇 |
眼科学 | 1391篇 |
药学 | 4955篇 |
36篇 | |
中国医学 | 2215篇 |
肿瘤学 | 3746篇 |
出版年
2024年 | 48篇 |
2023年 | 1205篇 |
2022年 | 1431篇 |
2021年 | 2762篇 |
2020年 | 3106篇 |
2019年 | 2973篇 |
2018年 | 2943篇 |
2017年 | 2931篇 |
2016年 | 2847篇 |
2015年 | 2934篇 |
2014年 | 5059篇 |
2013年 | 6011篇 |
2012年 | 4255篇 |
2011年 | 4967篇 |
2010年 | 4386篇 |
2009年 | 4351篇 |
2008年 | 4484篇 |
2007年 | 4723篇 |
2006年 | 4643篇 |
2005年 | 4116篇 |
2004年 | 3465篇 |
2003年 | 2925篇 |
2002年 | 2401篇 |
2001年 | 2056篇 |
2000年 | 1708篇 |
1999年 | 1342篇 |
1998年 | 1160篇 |
1997年 | 1067篇 |
1996年 | 969篇 |
1995年 | 935篇 |
1994年 | 949篇 |
1993年 | 631篇 |
1992年 | 724篇 |
1991年 | 550篇 |
1990年 | 404篇 |
1989年 | 400篇 |
1988年 | 363篇 |
1987年 | 294篇 |
1986年 | 222篇 |
1985年 | 289篇 |
1984年 | 238篇 |
1983年 | 149篇 |
1982年 | 155篇 |
1981年 | 141篇 |
1980年 | 109篇 |
1979年 | 83篇 |
1978年 | 101篇 |
1977年 | 69篇 |
1976年 | 70篇 |
1975年 | 48篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
《Transfusion and apheresis science》2022,61(2):103405
Transfusion-associated graft-versus-host disease (TA-GVHD) is a rare life-threatening complication of blood transfusion caused by donor T cells that escape rejection by the recipient immune system. These donor T cells drive recipient tissue damage in response to host antigens. On the other hand, GVHD occurring after allogeneic hematopoietic cell transplantation (HCT-GVHD) is also caused by donor T cells, but its pathophysiology is more complex and differs due to the effects of tissue damage caused by pre?HCT conditioning and profound immunosuppression. Both TA-GVHD and HCT-GVHD can be fatal; however, mortality is higher with TA-GVHD due to the paucity of treatment options. Here, we compare and summarize the presentation, diagnosis, pathophysiology, prevention, and treatment of TA-GVHD and HCT-GVHD. 相似文献
4.
5.
Xi Tian Yue Wang Wenhao Xu Haidan Tang Shuxuan Zhu Aihetaimujiang Anwaier Wangrui Liu Wenfeng Wang Wenkai Zhu Jiaqi Su Yuanyuan Qu Hailiang Zhang Dingwei Ye 《International journal of cancer. Journal international du cancer》2023,152(1):66-78
In clear cell renal cell carcinoma (ccRCC), glycolysis is enhanced mainly because of the increased expression of key enzymes in glycolysis. Hence, the discovery of new molecular biomarkers for glycolysis may help guide and establish a precise system of diagnosis and treatment for ccRCC. Expression profiles of 1079 tumor samples of ccRCC patients (including 311 patients treated with everolimus or nivolumab) were downloaded from public databases. Proteomic profiles of 232 ccRCC samples were obtained from Fudan University Shanghai Cancer Center (FUSCC). Biological changes, tumor microenvironment and prognostic differences were explored between samples with various glycolysis characteristics. There were significant differences in CD8+ effector T cells, epithelial-to-mesenchymal transition and pan-fibroblast TGFb between the Low and High glyScore groups. The tumor mutation burden of the Low glyScore group was lower than that of the High glyScore group. And higher glyScore was significantly associated with worse overall survival (OS) in 768 ccRCC patients (P < .0001). External validation in FUSCC cohort also indicated that glyScore was of strong ability for predicting OS (P < .05). GlyScore may serve as a biomarker for predicting everolimus response in ccRCC patients due to its significant associations with progression-free survival (PFS). And glyScore may also predict overall survival in patients treated with nivolumab. We calculated the glyScore in ccRCC and the defined glyScore was of strong ability for predicting OS. In addition, glyScore may also serve as a biomarker for predicting PFS in patients treated with everolimus and could predict OS in patients treated with nivolumab. 相似文献
6.
[摘要] 目的 评估直接抗病毒药物(direct antivirus agent, DAA)治疗肝移植术后HCV感染复发的有效性和安全性。方法?回顾性分析首都医科大学附属北京佑安医院2011年2月—2018年12月收治的14例肝移植术后HCV感染复发患者的DAA治疗临床数据,比较患者基线与治疗结束后肝肾功能、血常规、凝血功能、病毒学水平以及无创纤维化评分天冬氨酸转氨酶血小板比率指数(aspartate aminotransferase-platelet ratio index, APRI)的差异。利用电子病历系统和电话随访收集患者治疗期间不良反应发生情况。结果?所有患者均在治疗结束时达到病毒学清除,12周、24周持续病毒学应答率均为100%,DAA治疗后随访17~44个月,期间均未见病毒学复发。与基线水平相比,治疗终点时ALT、AST、TBIL、γ-谷氨酰转移酶以及无创纤维化评分APRI显著下降,WBC、HGB、PLT、CRE、肾小球滤过率和血糖等指标均未见显著变化。DAA治疗期间共3例患者发生不良反应,均为轻度,可自然缓解。结论?肝移植术后HCV感染复发的DAA治疗是安全有效的。 相似文献
7.
Kyung-Suk Suh Suk Kyun Hong Sola Lee Su young Hong Sanggyun Suh Eui Soo Han Seong-Mi Yang YoungRok Choi Nam-Joon Yi Kwang-Woong Lee 《American journal of transplantation》2022,22(1):260-265
Minimally invasive approaches are increasingly being applied in surgeries and have recently been used in living donor hepatectomy. We have developed a safe and reproducible method for minimally invasive living donor liver transplantation, which consists of pure laparoscopic explant hepatectomy and pure laparoscopic implantation of the graft, which was inserted through a suprapubic incision. Pure laparoscopic explant hepatectomy without liver fragmentation was performed in a 60-year-old man with alcoholic liver cirrhosis and hepatocellular carcinoma. The explanted liver was retrieved through a suprapubic incision. A modified right liver graft, procured from his 24-year-old son using the pure laparoscopic method, was inserted through a suprapubic incision, and implantation was performed intracorporeally throughout the procedure. The time required to remove the liver was 369 min, and the total operative time was 960 min. No complications occurred during or after the surgery. The patient recovered well, and his hospital stay was of 11 days. Pure laparoscopic living donor liver transplantation from explant hepatectomy to implantation was performed successfully. It is a feasible procedure when performed by a highly experienced surgeon and transplantation team. Further studies with larger sample sizes are needed to confirm its safety and feasibility.
8.
《Revista portuguesa de cardiologia》2022,41(4):311-320
Aims and objectivesVitamin D deficiency is a common finding and there is a suggested association with hypertension. Resistant hypertension is a clinical problem observed in 5–30% of hypertensive patients. Renal denervation (RDN) has been used for patients with resistant hypertension and has proven to lower blood pressure. Our primary goal was to assess the vitamin D serum concentration as a predictor of blood pressure response to RDN in highly selected patients.MethodsThis prospective, nonrandomized, single-center study included 24 patients treated with RDN. Based on their one-year response after RDN, patients were classified as responders or non-responders at six months or at 12 months.ResultsThe median follow-up was 52 months (range, 14-91 months). After RDN, 17 patients (70.8%) had a reduction >5 mmHg in the mean systolic blood pressure, at the first six months of follow-up. At 12 months, 20 patients (83.3%) were responders. Vitamin D levels at baseline (15.1±4.8 vs. 24.2±8.8 ng/ml) and at six months (16.6±7.2 vs. 25±9.2 ng/ml) were lower in early non-responders compared to early responders (p=0.008), without significant variation during follow-up. Even though Vitamin D levels were lower in the total responder's group, no statistically significant differences were found (p=ns).ConclusionIn patients with resistant hypertension, low vitamin D concentrations were associated with an absence of early response to RDN. 相似文献
9.
10.
《Transfusion and apheresis science》2022,61(1):103368
The endothelium is a single-layered structure that responds to physical and chemical signals with various factors it synthesizes. In the early days of its discovery, as the inner wall of the vessels, the endothelium was thought to be a simple barrier that lays on the surface. Over time it is discovered that endothelium maintains body homeostasis with the molecules it synthesizes, despite its simple single-layer structure. It has been accepted as an important organ that contributes to the maintenance of vascular tone, cell adhesion, inflammation, vascular permeability and coagulation. Any imbalance in these physiological and pathological events causes endothelial dysfunction. This can cause many diseases such as atherosclerosis, hypertension, diabetes, or it can occur because of these. Endothelial related disorders may also complicate hematopoietic stem cell transplantation (HSCT), which is used to treat various hematologic and neoplastic diseases. These life-threatening complications include graft-versus-host disease, hepatic veno-occlussive disease, transplant-associated thrombotic microangiopathy and diffuse alveolar hemorrhage. They share a similar pathophysiology involving endothelial cells with different clinical presentations. Therefore, current researche on the issue is putting the endothelium under the spotlight for novel markers and treatment options that should be used to monitor or treat at least some of these complications following HSCT. 相似文献